B+
Bull case
20%
Probability
Target price
$54.74
+16.7% vs current
KNSA
Kiniksa InternationalCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$36.49
-22.2% vs current
B-
Bear case
20%
Probability
Target price
$18.25
-61.1% vs current
AI sentiment snapshot
Latest data as of 2025-09-29
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+26.2
Score
AI commentary
Market tone is cautious-to-neutral: short-term focus centers on near-term filings and trial readouts while longer-term interest depends on BD activity and cash runway [#PR], [#10-Q]. Recent price action shows elevated volatility consistent with small-cap biotech peers when binary clinical events are pending [#yfinance].
RankAlpha Sentiment AI - 2025-09-29
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventQuarterly financial report / 10-Q / 8-K corporate updateHigh impact
Quarterly results and management commentary on cash runway, R&D milestones, and business-development progress; SEC filings and company press release are primary sources [#10-Q], [#PR].
-catalystTopline clinical readouts from pipeline studiesHigh impact
Efficacy/safety toplines from pivotal/phase 2b studies could cause binary moves depending on outcomes and labeling implications; monitor clinicaltrials.gov and company PRs [#NCT], [#PR].
-catalystBusiness development / licensing dealsHigh impact
Partnerships or out-licensing of assets would materially de-risk programs and often re-rate small-cap biotechs over multiple quarters [#PR].
Recommendation
N/A
No formal recommendation provided.
As of 2025-09-29 • Updated nightlySource: Internal modelMethodology